Reason:
In comparison to 5 years of tamoxifen alone, use of an AI in either primary, sequential, or extended treatment improves disease-free survival and reduces the risk of breast cancer events, including distant recurrence, locoregional recurrence, and contralateral breast cancer 
Strength of Recommendation:

Reason:
In comparison to 5 years of tamoxifen alone, use of an AI in either primary, sequential, or extended treatment improves disease-free survival and reduces the risk of breast cancer events, including distant recurrence, locoregional recurrence, and contralateral breast cancer
Logic:
If postmenopausal is [true] AND adjuvant treatment is [true] AND tamoxifen use is [false] Then consider taking an AI Recommendation 2 Conditional: The Update Committee recommends that patients who are initially treated with an AI but discontinue treatment before 5 years oftherapy consider taking tamoxifen for a total of 5 years of adjuvant endocrine therapy.
IF
Decidable Vocab AI
Value: true tamoxifen
Value: false THEN Executable Vocab consider tamoxifen for a duration of (5 years minus AI duration) years Evidence Quality:
Strength of Recommendation:
Reason:
The treatment regimen for patients in the sequencing trials spanned 5 years. No data support clinical benefits for durations of AIs longer than 2 or 3 years in a sequencing strategy. 
Logic
Reason:
Safety and efficacy data from the primary trials support up to 5 years of AI therapy as a primary adjuvant strategy, a duration used in two trials of extended therapy after 5 years of tamoxifen. 
Logic
Reason:
AI therapy has been shown tobe effective only in postmenopausal women and is contraindicated in patients with residual ovarian function. Patients accrued to ABCSG-12, the only trial to include premenopausal women, were all treatedwith gonadotropin-releasing hormone agonist therapy to achieve apostmenopausal state. Eligible patients had favorable prognosis and low-grade breast cancer, and none received adjuvant chemotherapy, though 5% did receive neoadjuvant chemotherapy. These patients are not necessarily representative of younger women with early-stage breast cancer. ABCSG-12 demonstrated equivalence with respect to time to recurrence, disease-free survival, and overall survival between tamoxifen and AI therapy in premenopausal women given ovarian suppression. Because of tamoxifen equivalence with AI therapy in that setting and the occasional failure to achieve menopausal status with ovarian uppression, the Update Committee strongly recommends tamoxifen as primary adjuvant endocrine therapy for all pre-or perimenopausal women and women with treatment-induced amenorrhea.
Logic:
If not menopausal OR 
Strength of Recommendation:
Reason:
In the absence of direct comparisons, the Update Committee interprets available data as suggesting that benefits of AI therapy represent a "class effect." Meaningful clinical differences between the commercially available thirdgeneration AIs have not been demonstrated to date.
Logic:
If postmenopausal AND intolerant of one AI AND still candidate for adjuvant endocrine therapy Then may be advised to consider tamoxifen OR may be advised to consider a different AI
